PLUR

Pluri Inc

Sep 17 • 04:00PM ET

4.70

-0.19 -3.84 %

Healthcare • Biotechnology • Israel • NASD

Peers: AAPL GOOGL MSFT AMZN TSLA META NVDA NFLX ORCL INTC

Index	-	P/E	-	EPS (ttm)	-3.61	Insider Own	49.45%	Shs Outstand	7.78M	Perf Week	-0.76%
Market Cap	36.81M	Forward P/E	-	EPS next Y	-	Insider Trans	33.70%	Shs Float	3.96M	Perf Month	-1.05%
Enterprise Value	46.28M	PEG	-	EPS next Q	-	Inst Own	17.50%	Short Float	0.61%	Perf Quarter	10.85%
Income	-20.71M	P/S	35.74	EPS this Y	-	Inst Trans	118.32%	Short Ratio	0.88	Perf Half Y	-0.51%
Sales	1.03M	P/B	-	EPS next Y	-	ROA	-56.14%	Short Interest	0.02M	Perf YTD	9.94%
Book/sh	-0.58	P/C	1.38	EPS next 5Y	-	ROE	-1205.58%	52W High	7.13 -34.08%	Perf Year	-9.79%
Cash/sh	3.41	P/FCF	-	EPS past 3/5Y	34.51% 29.51%	ROIC	-79.32%	52W Low	3.33 41.14%	Perf 3Y	-35.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 43.27%	Gross Margin	26.40%	Volatility	5.10% 7.16%	Perf 5Y	-94.05%
Dividend TTM	-	EV/Sales	44.93	EPS Y/Y TTM	13.57%	Oper. Margin	-2087.91%	ATR (14)	0.36	Perf 10Y	-96.88%
Dividend Ex-Date	-	Quick Ratio	4.81	Sales Y/Y TTM	203.23%	Profit Margin	-2003.29%	RSI (14)	45.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.81	EPS Q/Q	7.62%	SMA20	-6.07%	Beta	0.68	Target Price	12.00
Payout	-	Debt/Eq	-	Sales Q/Q	501.41%	SMA50	-6.92%	Rel Volume	0.42	Prev Close	4.89
Employees	118	LT Debt/Eq	-	Earnings	May 08	SMA200	-0.79%	Avg Volume	27.48K	Price	4.70
IPO	Apr 16, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	11,584	Change	-3.84%

Aug-14-25 04:30PM	Plurilock Announces Dates for Second Quarter 2025 Financial Results (Newsfile)
May-15-25 07:00AM	Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion (GlobeNewswire)
May-13-25 04:43PM	Pluri: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.32%
Apr-28-25 08:00AM	Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. (GlobeNewswire) -13.67%
Apr-11-25 10:37AM	Pluris immune cell expansion technologies gain patents (Pharmaceutical Technology)
08:30AM	Loading…
Apr-10-25 08:30AM	Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel (GlobeNewswire) -6.03%
Mar-05-25 07:00AM	Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness (GlobeNewswire) +5.86%
Feb-19-25 09:01AM	Ever After Foods and Buhler Collaborate to Scale Cultivated Meat Production and Distribution (GlobeNewswire)
09:01AM	Ever After Foods and B hler Collaborate to Scale Cultivated Meat Production and Distribution (GlobeNewswire)
Feb-11-25 05:37PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-04-25 07:00AM	Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million (GlobeNewswire)
Jan-24-25 09:25AM	Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market (TipRanks)
Jan-23-25 07:15AM	Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition (GlobeNewswire) +6.40%
Dec-19-24 08:00AM	Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease (GlobeNewswire)
Dec-09-24 09:00AM	Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 (GlobeNewswire)
03:45PM	Loading…
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
Nov-25-24 08:30AM	Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns (GlobeNewswire) +7.55%
Nov-12-24 05:52PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +8.43% +9.22%
01:00PM	Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Nov-11-24 06:00AM	BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing (PR Newswire) +11.92%
Oct-28-24 07:00AM	Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority (GlobeNewswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Jul-18-24 02:30AM	Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates (GlobeNewswire)
Jul-08-24 07:00AM	Pluri Announces 1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply (GlobeNewswire)
Jun-18-24 06:30AM	Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges (GlobeNewswire)
Jun-06-24 06:45AM	U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract (GlobeNewswire)
May-20-24 07:00AM	Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale (GlobeNewswire)
May-02-24 07:00AM	Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment (GlobeNewswire) +5.03%
Apr-08-24 07:00AM	Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method (GlobeNewswire)
Apr-03-24 02:52PM	PLUR Stock Earnings: Pluri Reported Results for Q4 2023 (InvestorPlace) -8.70%
07:15AM	Loading…
Mar-28-24 07:15AM	Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences (GlobeNewswire) -8.39%
Mar-27-24 07:00AM	Pluri Inc. Announces 1-for-8 Reverse Share Split (GlobeNewswire) -13.75%
Mar-21-24 07:00AM	Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report (GlobeNewswire)
Mar-19-24 04:00AM	Engage with Pluri's Talent: Exciting Conference Appearances Ahead (GlobeNewswire)
Mar-14-24 07:00AM	Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing (GlobeNewswire)
Mar-11-24 07:00AM	Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation (GlobeNewswire)
Mar-06-24 07:00AM	Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board (GlobeNewswire) +13.77%
Feb-28-24 07:00AM	Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals (GlobeNewswire)
Feb-12-24 05:20PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.49%
Jan-23-24 02:00AM	Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (GlobeNewswire) +15.81%
Jan-08-24 07:00AM	Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization (GlobeNewswire) -6.79%
Dec-21-23 07:00AM	Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction (GlobeNewswire)
Nov-13-23 07:29PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.99%
Aug-16-23 07:00AM	Pluris PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation (GlobeNewswire)
Jul-13-23 02:00AM	Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors (GlobeNewswire) +5.54%
Jul-12-23 11:17AM	Deutsche Bank Predicts up to 160% Rally for These 3 Stocks Heres Why They Have Solid Upside (TipRanks) -5.25%
Jul-11-23 02:00AM	U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome (GlobeNewswire) +8.91%
Apr-27-23 07:00AM	Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products (GlobeNewswire)
Mar-13-23 08:00AM	Israels Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity (GlobeNewswire)
Dec-22-22 07:00AM	Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept (GlobeNewswire)
Dec-15-22 04:05PM	Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.30%
Nov-10-22 07:00AM	Pluri wins BioTech Breakthrough Cell Innovation of the Year Award (GlobeNewswire) +8.10%
Oct-31-22 08:00AM	Pluri to Present and Participate in Upcoming Conferences (GlobeNewswire)
Sep-29-22 07:00AM	Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates (GlobeNewswire)
Sep-06-22 07:00AM	7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluris PLX-PAD Cells for Osteoarthritis Treatment (GlobeNewswire)
Apr-07-22 07:00AM	Plurilock's Aurora Systems Receives US$224,000 Purchase Order from the U.S. Library of Congress (Newsfile)
Apr-01-22 07:00AM	Plurilock Names Garr Stephenson Jr. as Chief Revenue Officer (Newsfile)
Mar-31-22 07:00AM	Plurilock's Aurora Systems Receives US$1.5 Million Purchase Order from the U.S. Department of Defense (Newsfile)
Mar-28-22 07:00AM	Plurilock Submits Non-Provisional U.S. Patent Application for Multi-Device Identity Confirmation Technology (Newsfile)
Mar-23-22 07:00AM	Plurilock's Aurora Systems Receives US$1.85 Million Purchase Order from the U.S. Department of the Navy (Newsfile)
Mar-17-22 07:00AM	Plurilock Adds Brandon Swafford to Advisory Board (Newsfile)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manieu Alexandre Weinstein	Director	Apr 28 '25	Buy	4.61	976,139	4,500,001	931,246	Jul 01 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLUR

Pluri Inc

Upgrade your FINVIZ experience